Combining Histone Deacetylase Inhibitors with Other Cancer Treatments
Author Information
Author(s): Nolan L, Johnson P W M, Ganesan A, Packham G, Crabb S J
Primary Institution: Cancer Research UK Clinical Centre, School of Medicine, University of Southampton
Hypothesis
In most scenarios, combination with other therapeutic modalities will be required to optimise efficacy of histone deacetylase inhibitors.
Conclusion
Histone deacetylase inhibitors show promise when combined with various anticancer agents, potentially enhancing their effectiveness.
Supporting Evidence
- Histone deacetylase inhibitors have shown modest antitumor activity in initial clinical trials.
- Combination with cytotoxic chemotherapy has demonstrated synergistic effects in pre-clinical models.
- Clinical trials are ongoing to evaluate the effectiveness of HDI combinations with various agents.
Takeaway
Histone deacetylase inhibitors are like helpers for cancer treatments, making them work better when used together.
Methodology
This review discusses the mechanisms and evidence supporting the combination of HDAC inhibitors with other cancer therapies.
Limitations
The study primarily relies on pre-clinical data and early-phase clinical trials, limiting the generalizability of findings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website